Millennium Management’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.66M | Buy |
199,524
+147,587
| +284% | +$3.21M | ﹤0.01% | 3025 |
|
|
2025
Q4 | $1.09M | Sell |
51,937
-994,519
| -95% | -$17.3M | ﹤0.01% | 4425 |
|
|
2025
Q3 | $16.1M | Sell |
1,046,456
-552,157
| -35% | -$7.23M | 0.01% | 1912 |
|
|
2025
Q2 | $15M | Buy |
1,598,613
+1,169,961
| +273% | +$12.9M | 0.01% | 1857 |
|
|
2025
Q1 | $5.27M | Sell |
428,652
-158,158
| -27% | -$2.23M | ﹤0.01% | 2813 |
|
|
2024
Q4 | $7.76M | Sell |
586,810
-533,153
| -48% | -$9.12M | ﹤0.01% | 2418 |
|
|
2024
Q3 | $21.6M | Buy |
1,119,963
+54,455
| +5% | +$1.13M | 0.01% | 1493 |
|
|
2024
Q2 | $21.9M | Buy |
1,065,508
+383,634
| +56% | +$8.03M | 0.01% | 1415 |
|
|
2024
Q1 | $16.2M | Sell |
681,874
-260,768
| -28% | -$5.82M | 0.01% | 1729 |
|
|
2023
Q4 | $20.4M | Buy |
942,642
+502,872
| +114% | +$7.73M | 0.01% | 1532 |
|
|
2023
Q3 | $6.39M | Buy |
439,770
+288,070
| +190% | +$5.45M | ﹤0.01% | 2470 |
|
|
2023
Q2 | $3.18M | Buy |
151,700
+109,972
| +264% | +$2.29M | ﹤0.01% | 3090 |
|
|
2023
Q1 | $881K | Buy |
+41,728
| New | +$1.04M | ﹤0.01% | 4203 |
|
|
2022
Q3 | – | Sell |
-24,601
| Closed | -$473K | – | 7455 |
|
|
2022
Q2 | $473K | Sell |
24,601
-401,512
| -94% | -$6.69M | ﹤0.01% | 4995 |
|
|
2022
Q1 | $7.41M | Buy |
426,113
+407,351
| +2,171% | +$6.86M | ﹤0.01% | 2499 |
|
|
2021
Q4 | $411K | Sell |
18,762
-18,089
| -49% | -$334K | ﹤0.01% | 5244 |
|
|
2021
Q3 | $704K | Sell |
36,851
-166,994
| -82% | -$2.78M | ﹤0.01% | 5014 |
|
|
2021
Q2 | $3.5M | Buy |
+203,845
| New | +$3.73M | ﹤0.01% | 3239 |
|
|
2021
Q1 | – | Sell |
-757,147
| Closed | -$16.8M | – | 6464 |
|
|
2020
Q4 | $16.8M | Sell |
757,147
-52,143
| -6% | -$1.08M | 0.01% | 1217 |
|
|
2020
Q3 | $11.9K | Sell |
809,290
-52,758
| -6% | -$804K | 0.01% | 1118 |
|
|
2020
Q2 | $12.8M | Buy |
862,048
+580,957
| +207% | +$8.85M | 0.02% | 1046 |
|
|
2020
Q1 | $3.08M | Buy |
281,091
+252,070
| +869% | +$2.37M | 0.01% | 1712 |
|
|
2019
Q4 | $255K | Sell |
29,021
-1,774
| -6% | -$13K | ﹤0.01% | 3747 |
|
|
2019
Q3 | $230K | Sell |
30,795
-10,282
| -25% | -$93.7K | ﹤0.01% | 3722 |
|
|
2019
Q2 | $382K | Sell |
41,077
-26,078
| -39% | -$190K | ﹤0.01% | 3405 |
|
|
2019
Q1 | $353K | Buy |
67,155
+16,690
| +33% | +$95.2K | ﹤0.01% | 3460 |
|
|
2018
Q4 | $225K | Sell |
50,465
-557,573
| -92% | -$3.06M | ﹤0.01% | 3356 |
|
|
2018
Q3 | $4.91M | Buy |
608,038
+459,103
| +308% | +$3.27M | 0.01% | 1806 |
|
|
2018
Q2 | $1.05M | Sell |
148,935
-192,378
| -56% | -$1.89M | ﹤0.01% | 2810 |
|
|
2018
Q1 | $4.86M | Sell |
341,313
-175,187
| -34% | -$1.86M | 0.01% | 1825 |
|
|
2017
Q4 | $4.53M | Buy |
516,500
+82,256
| +19% | +$814K | 0.01% | 1788 |
|
|
2017
Q3 | $5.08M | Sell |
434,244
-326,959
| -43% | -$4.01M | 0.01% | 1663 |
|
|
2017
Q2 | $10.6M | Buy |
761,203
+463,723
| +156% | +$5.3M | 0.02% | 1028 |
|
|
2017
Q1 | $4.08M | Buy |
297,480
+197,415
| +197% | +$2.05M | 0.01% | 1573 |
|
|
2016
Q4 | $717K | Buy |
+100,065
| New | +$1.1M | ﹤0.01% | 2442 |
|
|
2016
Q3 | – | Sell |
-13,879
| Closed | -$137K | – | 3577 |
|
|
2016
Q2 | $137K | Sell |
13,879
-33,235
| -71% | -$456K | ﹤0.01% | 2975 |
|
|
2016
Q1 | $628K | Buy |
+47,114
| New | +$592K | ﹤0.01% | 2407 |
|
Other funds holding SNDX
KCM
VCM
DM
EP
KCM
HRCM
Millennium Management's SNDX Position: Q1 2026 in Review
Millennium Management increased its Syndax Pharmaceuticals (SNDX) stake by 284% in Q1 2026, buying an estimated $3.21M and bringing the position to 199,524 shares worth $4.66M. The position accounts for ﹤0.01% of the portfolio, ranked #3025.
Millennium Management first reported a position in SNDX in Q1 2016 and has held it in 37 quarters since. The position peaked at $21.9M in Q2 2024. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.
- Millennium Management held 199,524 shares of Syndax Pharmaceuticals worth $4.66M as of Q1 2026.
- Millennium Management bought 147,587 Syndax Pharmaceuticals shares in Q1 2026, an estimated $3.21M.
- Syndax Pharmaceuticals made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3025 holding.
- Millennium Management first reported a position in Syndax Pharmaceuticals in Q1 2016 and has held it in 37 quarters since.
- Millennium Management's Syndax Pharmaceuticals position peaked at $21.9M in Q2 2024.
- 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.